Association of metformin treatment with changes in metal dynamics in individuals with type 2 diabetes.

IF 4.1 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Natsu Otowa-Suematsu, Kazuhiko Sakaguchi, Tomoko Yamada, Marika Nishisaka, Yasuko Morita, Hayato Fukumitsu, Yukari Katsura, Yuko Okada, Yushi Hirota, Kenji Sugawara, Wataru Ogawa
{"title":"Association of metformin treatment with changes in metal dynamics in individuals with type 2 diabetes.","authors":"Natsu Otowa-Suematsu, Kazuhiko Sakaguchi, Tomoko Yamada, Marika Nishisaka, Yasuko Morita, Hayato Fukumitsu, Yukari Katsura, Yuko Okada, Yushi Hirota, Kenji Sugawara, Wataru Ogawa","doi":"10.1136/bmjdrc-2025-005255","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The metal-chelating activity of metformin, which has long been known but of unclear clinical relevance, has recently been implicated in the pleiotropic effects, including antitumorigenic and anti-inflammatory actions, of the drug. However, whether metformin actually influences metal dynamics in humans has remained unknown. We here investigate whether metformin influences serum metal levels in individuals with type 2 diabetes.</p><p><strong>Research design and methods: </strong>In this cross-sectional study, individuals with type 2 diabetes treated or not treated with metformin for at least 6 months were recruited. The primary outcome was the difference in serum copper concentration between metformin users and non-users. Secondary outcomes included differences in serum levels of iron, zinc, and vitamin B<sub>12</sub> as well as in copper-related and iron-related parameters between the two groups.</p><p><strong>Results: </strong>A total of 189 individuals (93 metformin users and 96 non-users) were analyzed. Metformin users showed significantly lower serum copper (16.0 vs 17.8 µmol/L, p<0.001) and iron levels (16.3 vs 17.3 µmol/L, p=0.02) and higher zinc levels (13.3 vs 12.5 µmol/L, p=0.01) compared with non-users. Copper-related and iron-related parameters for metformin users were consistent with latent deficiencies of these metals. Serum homocysteine levels (12.2 vs 11.2 µmol/L, p=0.03) were significantly higher, whereas vitamin B<sub>12</sub> levels (338.7 vs 412.8 pmol/L, p<0.001) were significantly lower, in metformin users. Multiple regression analysis including variables that potentially influence metal dynamics identified metformin use as an independent predictor of serum copper (B = -1.54 µmol/L, p<0.001) and iron levels (B = -2.49 µmol/L, p=0.004).</p><p><strong>Conclusions: </strong>Metformin use was associated with reduced serum levels of copper and iron, as well as with increased serum zinc levels. These changes in metal dynamics may be related to the pharmacological effects of this widely administered drug.</p>","PeriodicalId":9151,"journal":{"name":"BMJ Open Diabetes Research & Care","volume":"13 5","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406903/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Diabetes Research & Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjdrc-2025-005255","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The metal-chelating activity of metformin, which has long been known but of unclear clinical relevance, has recently been implicated in the pleiotropic effects, including antitumorigenic and anti-inflammatory actions, of the drug. However, whether metformin actually influences metal dynamics in humans has remained unknown. We here investigate whether metformin influences serum metal levels in individuals with type 2 diabetes.

Research design and methods: In this cross-sectional study, individuals with type 2 diabetes treated or not treated with metformin for at least 6 months were recruited. The primary outcome was the difference in serum copper concentration between metformin users and non-users. Secondary outcomes included differences in serum levels of iron, zinc, and vitamin B12 as well as in copper-related and iron-related parameters between the two groups.

Results: A total of 189 individuals (93 metformin users and 96 non-users) were analyzed. Metformin users showed significantly lower serum copper (16.0 vs 17.8 µmol/L, p<0.001) and iron levels (16.3 vs 17.3 µmol/L, p=0.02) and higher zinc levels (13.3 vs 12.5 µmol/L, p=0.01) compared with non-users. Copper-related and iron-related parameters for metformin users were consistent with latent deficiencies of these metals. Serum homocysteine levels (12.2 vs 11.2 µmol/L, p=0.03) were significantly higher, whereas vitamin B12 levels (338.7 vs 412.8 pmol/L, p<0.001) were significantly lower, in metformin users. Multiple regression analysis including variables that potentially influence metal dynamics identified metformin use as an independent predictor of serum copper (B = -1.54 µmol/L, p<0.001) and iron levels (B = -2.49 µmol/L, p=0.004).

Conclusions: Metformin use was associated with reduced serum levels of copper and iron, as well as with increased serum zinc levels. These changes in metal dynamics may be related to the pharmacological effects of this widely administered drug.

二甲双胍治疗与2型糖尿病患者金属动力学变化的关系
导读:二甲双胍的金属螯合活性早已为人所知,但其临床意义尚不明确,最近人们发现二甲双胍具有多种作用,包括抗肿瘤和抗炎作用。然而,二甲双胍是否真的影响人体的金属动力学仍然未知。我们在此研究二甲双胍是否会影响2型糖尿病患者的血清金属水平。研究设计和方法:在这项横断面研究中,招募了接受二甲双胍治疗或未接受二甲双胍治疗至少6个月的2型糖尿病患者。主要结局是二甲双胍服用者和非服用者血清铜浓度的差异。次要结果包括两组之间血清铁、锌和维生素B12水平以及铜和铁相关参数的差异。结果:共分析189例患者,其中使用二甲双胍者93例,未使用二甲双胍者96例。二甲双胍使用者血清铜水平显著降低(16.0 vs 17.8 μ mol/L, p12) (338.7 vs 412.8 pmol/L)。结论:二甲双胍使用与血清铜和铁水平降低以及血清锌水平升高有关。这些金属动力学的变化可能与这种广泛使用的药物的药理作用有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
9.30
自引率
2.40%
发文量
123
审稿时长
18 weeks
期刊介绍: BMJ Open Diabetes Research & Care is an open access journal committed to publishing high-quality, basic and clinical research articles regarding type 1 and type 2 diabetes, and associated complications. Only original content will be accepted, and submissions are subject to rigorous peer review to ensure the publication of high-quality — and evidence-based — original research articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信